List of Excipients in Branded Drug EPIPEN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Viatris Specialty LLC	EPIPEN	epinephrine	49502-500	HYDROCHLORIC ACID
Viatris Specialty LLC	EPIPEN	epinephrine	49502-500	SODIUM CHLORIDE
Viatris Specialty LLC	EPIPEN	epinephrine	49502-500	SODIUM METABISULFITE

EpiPen Excipient Strategy and Commercial Opportunities

Last updated: August 1, 2026

EpiPen is an epinephrine auto-injector whose formulation uses a small excipient system: sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection. The largest commercial opportunities are not conventional excipient substitution alone. They are in sulfite management, oxidation control, long-term stability, device compatibility, pediatric dose differentiation, and development of preservative-free or lower-sensitization presentations.

EpiPen’s core formulation is technically simple but commercially difficult to replicate. The product combines a chemically sensitive active ingredient with a spring-driven delivery device, a narrow injection-volume target, sterile manufacturing requirements, and high reliability expectations in emergency use. Excipient suppliers and drug-device developers can capture value by solving stability and container-closure problems without changing the delivered epinephrine dose.

What excipients are used in EpiPen?

The EpiPen and EpiPen Jr labels identify epinephrine, sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection as formulation components.[1]

Component	Function in EpiPen formulation	Commercial relevance
Epinephrine	Active pharmaceutical ingredient	Oxidation-sensitive catecholamine requiring control of light, oxygen, pH, and trace metals
Sodium chloride	Tonicity agent	Supports isotonicity and injection tolerability
Sodium metabisulfite	Antioxidant	Controls oxidative degradation of epinephrine
Hydrochloric acid	pH adjustment	Maintains an acidic formulation environment favorable to epinephrine stability
Water for injection	Vehicle	Sterile aqueous medium

EpiPen is supplied as a sterile epinephrine solution for intramuscular or subcutaneous injection. The labeled pH range is approximately 2.5 to 5.0.[1] The product is not a complex depot, suspension, biologic, or modified-release system. Its formulation risk is concentrated in chemical stability, sterility, dose accuracy, and device performance.

Why is sodium metabisulfite used in EpiPen?

Sodium metabisulfite is used as an antioxidant to limit oxidative degradation of epinephrine. Epinephrine can oxidize to adrenochrome and related degradation products, with associated discoloration and loss of potency.

The preservative creates a regulatory and commercial tradeoff. Sulfites can cause hypersensitivity reactions in susceptible individuals, particularly patients with asthma. The EpiPen label states that the presence of a sulfite should not prevent administration in a life-threatening allergic reaction, because the sulfite-associated risk is considered less significant than untreated anaphylaxis.[1]

This creates a potential product-development opening for:

• Lower-sulfite formulations.
• Sulfite-free formulations.
• Alternative antioxidant systems.
• Improved oxygen-barrier cartridges.
• Low-metal-contact primary packaging.
• Formulations with reduced headspace oxygen.
• Device systems that reduce extractables and leachables.

A sulfite-free product would not be a simple line extension. The developer would need to show equivalent or superior potency retention, impurity control, sterility assurance, container-closure integrity, and device shelf life.

What formulation patents protect EpiPen?

EpiPen protection has historically been concentrated in the drug-device combination, injector architecture, manufacturing process, and regulatory exclusivity rather than in a broad, high-value excipient patent estate.

The listed formulation ingredients are conventional pharmaceutical excipients. Sodium chloride, hydrochloric acid, water for injection, and sodium metabisulfite generally do not create strong standalone composition-of-matter protection when used in a conventional epinephrine solution.

The commercially relevant intellectual-property categories are:

IP category	Potential scope	Relevance to excipient strategy
Combination-product patents	Epinephrine formulation combined with an auto-injector	Can limit copying of the complete product even when the formulation is conventional
Device patents	Needle deployment, activation, safety mechanisms, dose delivery, housing, and packaging	Often more important than excipient patents
Formulation patents	Specific pH, antioxidant system, impurity limits, stability profile, or container interaction	Can protect a differentiated sulfite-free or low-sulfite product
Manufacturing patents	Sterile filling, cartridge assembly, oxygen control, and device loading	Can create barriers where the formulation itself is unpatentable
Method-of-use patents	Use in anaphylaxis or emergency allergic reactions	Generally weaker for generic competition where the use is already established
Trade secrets	Filling parameters, oxygen management, inspection criteria, device assembly, and stability controls	Can preserve manufacturing advantages without public disclosure

The patent analysis should distinguish patents listed for the drug-device product from patents directed specifically to excipients. A competitor can often avoid a formulation claim by changing the antioxidant, pH range, oxygen-control method, or packaging while retaining the same epinephrine dose.

How strong is the EpiPen patent estate?

The EpiPen patent estate is stronger as a combination-product and device estate than as an excipient estate.

The FDA approved Teva’s generic version of EpiPen and EpiPen Jr in 2018, confirming that the product could be challenged through an abbreviated pathway despite the commercial importance of the device.[2] Authorized generic and other generic competition has since reduced the exclusivity value of the original EpiPen brand.

Patent-strength assessment

Area	Relative strength	Reason
Epinephrine active ingredient	Low	Long-established molecule
Basic aqueous formulation	Low	Conventional excipient system
Sodium metabisulfite use	Low to moderate	Functional use is established, but specific concentration and stability claims may be protectable
Sulfite-free formulation	Moderate to high if technically differentiated	Stability, impurity, and shelf-life data can support narrower claims
Auto-injector mechanics	Moderate to high	Device geometry and activation systems may support enforceable claims
Cartridge and container system	Moderate	Oxygen ingress, siliconization, extractables, and closure configuration can be claimed
Manufacturing process	Moderate	Sterile assembly and filling processes may create practical barriers
Method of use	Low to moderate	Anaphylaxis use is well established and vulnerable to prior art

A new entrant should not rely on an excipient change alone to create durable exclusivity. The strongest strategy combines a differentiated formulation with a delivery device, primary-container design, manufacturing process, and clinically meaningful labeling distinction.

What excipient strategies could differentiate a next-generation EpiPen?

1. Sulfite-free epinephrine

The clearest formulation opportunity is a sulfite-free epinephrine auto-injector. The value proposition would target patients and prescribers concerned about sulfite exposure while preserving rapid delivery and long shelf life.

The primary technical problem is oxidation. A sulfite-free product may require a combination of:

• Lower oxygen exposure during compounding and filling.
• Nitrogen or inert-gas overlay.
• Low-oxygen headspace.
• Higher-barrier cartridge materials.
• Improved elastomer closures.
• Chelation of trace metals where compatible with the formulation.
• Tighter control of light exposure.
• Alternative antioxidants with acceptable injection safety.
• A narrower pH target.
• Lower extractables from the device and cartridge.

The formulation developer would need to demonstrate that any alternative antioxidant does not create new toxicology, immunogenicity, particulate, or compatibility concerns.

2. Alternative antioxidant systems

Potential antioxidant approaches include ascorbate-based systems, thiol-containing compounds, chelators, or oxygen-control strategies. Each presents a different regulatory burden.

A new antioxidant may create patentable composition claims, but it also adds:

• New impurity pathways.
• Additional analytical methods.
• More extractables and leachables questions.
• New toxicological justification.
• Possible discoloration or precipitation.
• Greater risk of interaction with the injector’s cartridge, stopper, needle, or lubricant.

An oxygen-management strategy may offer a cleaner regulatory path than introducing a novel injectable excipient. The tradeoff is that packaging and manufacturing claims may be narrower and more difficult to enforce independently.

3. Lower-sulfite formulations

A reduced-sulfite product may be easier to develop than a completely sulfite-free product. It could preserve some oxidation protection while lowering sulfite exposure.

The commercial challenge is differentiation. A modest reduction may not justify a new prescription product unless supported by:

• A clear labeling distinction.
• Improved stability or shelf life.
• A clinically relevant tolerability benefit.
• A payer or institutional purchasing advantage.
• A proprietary device or presentation.

4. Improved pH control

Epinephrine stability depends heavily on pH. A developer could seek claims covering a narrow pH range linked to impurity control and shelf-life performance.

A pH-based patent strategy is vulnerable if the claimed range is an expected optimization or if prior art discloses overlapping ranges. The claim becomes stronger when the developer can establish an unexpected stability advantage, a defined impurity profile, or a device-specific compatibility result.

5. Low-extractables and low-leachables systems

Epinephrine auto-injectors contain several materials that can affect product quality:

• Glass or polymer cartridge components.
• Elastomeric plungers and seals.
• Needle adhesives.
• Lubricants.
• Plastic housing components.
• Protective caps and packaging materials.

A low-extractables formulation and cartridge system can support a differentiated product where the interaction between formulation and device is documented. Claims may cover the combination of formulation, material composition, oxygen transmission rate, and storage conditions.

What FDA regulatory pathway applies to EpiPen competitors?

EpiPen is a drug-device combination product. FDA-approved competitors generally need to establish both pharmaceutical equivalence and device performance, although the precise pathway depends on the product’s design and regulatory classification.

The major pathways are:

Pathway	Typical use	Strategic implication
ANDA	Generic epinephrine auto-injector referencing EpiPen	Favors products with the same active ingredient, strength, route, dosage form, and comparable device performance
505(b)(2) NDA	Modified formulation, device, or presentation with reliance on existing data	More flexible for sulfite-free or materially redesigned products
351(a) or 351(k) biologic pathways	Not applicable to standard epinephrine	Biosimilar competition is not relevant
De novo or device pathway	Generally not the principal route for the drug product	The epinephrine solution remains subject to drug regulation

A sulfite-free product, materially different device, new dose presentation, or clinically differentiated formulation may fit better under a 505(b)(2) strategy than an ANDA. The commercial benefit is greater formulation and device flexibility. The cost is additional development, clinical, and regulatory work.

What is the Orange Book status of EpiPen?

The FDA Orange Book identifies approved drug products and applicable patent and exclusivity information. EpiPen-related products must be reviewed by exact application number, strength, dosage form, and sponsor because the regulatory record has changed as generic and authorized-generic products entered the market.[3]

The key Orange Book questions are:

1. Which New Drug Application covers the branded EpiPen product?
2. Which patents, if any, remain listed against the relevant NDA?
3. Are the listed patents formulation patents, device patents, or method-of-use patents?
4. Which patents have expired or been delisted?
5. What Paragraph IV certifications were submitted by generic applicants?
6. Did any listed patent trigger a 30-month stay?
7. Are the relevant patents applicable to both EpiPen and EpiPen Jr?

For an excipient-focused entrant, Orange Book review is necessary but not sufficient. Device patents, continuation patents, design patents, foreign patents, and trade-secret manufacturing controls may sit outside the narrow formulation analysis.

When did generic EpiPen competition begin?

FDA approved Teva Pharmaceuticals’ generic epinephrine auto-injector in 2018 for the 0.3 mg and 0.15 mg strengths.[2] The approval created direct generic competition to EpiPen and EpiPen Jr.

The commercial launch environment also includes:

• Mylan/Viatris-branded EpiPen.
• Authorized generic versions.
• Teva’s generic epinephrine auto-injector.
• Other approved or marketed epinephrine auto-injector products.
• Alternative delivery systems such as prefilled syringes and manual epinephrine injections.

Generic entry reduces the value of conventional formulation replication. New entrants need either lower cost, better device usability, improved stability, differentiated excipient risk, or superior channel access.

Which companies are challenging EpiPen?

Teva was the most prominent early generic challenger, receiving FDA approval for a generic EpiPen and EpiPen Jr in 2018.[2] Viatris and its predecessor Mylan also commercialized authorized-generic versions.

Competition is not limited to patent litigation. Market access can be affected by:

• FDA approval timing.
• Device manufacturing capacity.
• Pharmacy substitution rules.
• School and emergency-response procurement.
• Insurance formulary placement.
• Device recall history.
• Product shortages.
• Patient and caregiver training.
• Contracting with wholesalers and pharmacy benefit managers.

Because EpiPen is an emergency product, reliability and availability can outweigh a modest price difference. A new product needs a credible supply and device-training program.

What patent litigation and settlement issues affect EpiPen?

EpiPen competition has included patent disputes and commercial challenges involving the injector product and competing generic products. The most relevant legal issues are:

• Paragraph IV challenges to listed patents.
• Patent litigation under the Hatch-Waxman framework.
• Authorized-generic arrangements.
• Settlement terms affecting launch timing.
• Device patent assertions.
• Antitrust scrutiny involving product switching or patent-listing conduct.
• Regulatory disputes over substitutability and device equivalence.

Settlement agreements may create launch dates that differ from patent expiration dates. A commercial forecast should therefore model at least three dates:

Date type	Meaning
Patent expiration	End of enforceable patent term, subject to claim scope and litigation outcome
Earliest permitted launch	Date established by settlement, court order, or regulatory outcome
Commercial launch date	Actual date when product is available at meaningful scale

The patent expiry date alone does not predict market entry.

What manufacturing and IP barriers exist for EpiPen excipient suppliers?

The principal manufacturing barriers are not the cost of sodium chloride or sodium metabisulfite. They are process control and integrated product performance.

Critical manufacturing controls

• Sterile compounding and filling.
• Oxygen control during manufacture.
• Accurate epinephrine concentration.
• Uniform fill volume.
• Cartridge and stopper compatibility.
• Device assembly under controlled conditions.
• Needle and spring reliability.
• Container-closure integrity.
• Particulate control.
• Stability under heat, cold, vibration, and light.
• End-of-shelf-life injector activation.

An excipient supplier can create value by offering a qualified platform rather than a commodity ingredient. The platform could include low-metal-grade sodium metabisulfite, controlled peroxide specifications, reduced bioburden, low endotoxin, validated compatibility data, and support for sterile filling.

How does EpiPen compare with competing epinephrine products?

Product type	Formulation opportunity	Device opportunity	Competitive position
Traditional EpiPen-style auto-injector	Sulfite reduction and oxidation control	Familiar spring-driven auto-injector	Strong user familiarity
Generic auto-injector	Usually formulation equivalence	Device equivalence and lower price	Price-led competition
Prefilled syringe	Lower device complexity	Manual administration	May reduce device cost but requires trained administration
New-generation compact injector	Reformulated or standard solution	Smaller, simpler, or voice-guided system	Potential adherence and usability differentiation
Sulfite-free auto-injector	Alternative antioxidant or packaging strategy	Same or redesigned injector	Premium niche with formulation differentiation

A sulfite-free auto-injector has the strongest potential to create a new product category, but it also carries the highest stability and regulatory burden.

What revenue exposure does EpiPen create for formulation and excipient suppliers?

EpiPen is a high-volume emergency product, but excipient value per unit is low. A supplier should not base its commercial case on ingredient price alone.

Higher-value opportunities include:

1. Qualification as a dual-source supplier for sodium metabisulfite or other critical excipients.
2. Supply of low-peroxide, low-metal, or low-bioburden grades.
3. Development partnerships for sulfite-free epinephrine.
4. Container and closure systems with improved oxygen protection.
5. Stability-indicating analytical packages.
6. Contract formulation and sterile filling.
7. Integrated cartridge and injector compatibility programs.
8. Pediatric and adult presentation development.
9. International supply for markets with different device and labeling requirements.

The addressable market is larger for a differentiated finished product than for a commodity excipient. A formulation company can capture more value by licensing a complete stability and packaging platform to an auto-injector manufacturer.

What generic launch scenarios exist for EpiPen?

Scenario 1: Price-led generic entry

A conventional generic uses the established excipient system and competes through price, contracting, and distribution. This is the lowest-risk formulation strategy and the weakest source of patent differentiation.

Scenario 2: Authorized-generic expansion

An authorized generic uses the branded product or a closely related product under a separate label. This can preserve manufacturing scale while competing in generic channels.

Scenario 3: 505(b)(2) sulfite-reduced product

A developer introduces a lower-sulfite formulation with supporting stability and safety data. The product may command a premium if the labeling and clinical positioning are meaningful.

Scenario 4: Sulfite-free combination product

A new formulation and injector are protected through composition, packaging, device, and manufacturing claims. This offers the strongest commercial differentiation but requires the largest development investment.

Scenario 5: Non-auto-injector alternative

A prefilled syringe or other delivery system competes on cost and procurement simplicity. Its main barrier is user handling during anaphylaxis, not excipient technology.

Key Takeaways

• EpiPen uses a conventional aqueous epinephrine formulation containing sodium chloride, sodium metabisulfite, hydrochloric acid, and water for injection.
• Sodium metabisulfite is the main excipient with a clear product-positioning issue because of sulfite hypersensitivity concerns.
• The strongest formulation opportunity is a sulfite-free or sulfite-reduced product supported by oxygen control, packaging, and device compatibility.
• EpiPen’s protection is more significant at the drug-device and injector level than at the basic excipient level.
• Teva’s 2018 FDA approval established direct generic competition.
• Biosimilar risk does not apply because epinephrine is a small-molecule drug, not a biologic.
• A conventional excipient substitution is unlikely to provide durable commercial protection without linked patents covering stability, packaging, manufacturing, or the injector.
• The most valuable commercial position is an integrated formulation-device platform rather than a commodity excipient supply contract.
• Market-entry forecasts must separate patent expiration, settlement-based launch rights, FDA approval, and actual commercial availability.

FAQs About EpiPen Excipient and Formulation Opportunities

Is EpiPen preservative-free?

EpiPen is a sterile single-dose product, but its formulation contains sodium metabisulfite as an antioxidant. Sodium metabisulfite is not used as a conventional antimicrobial preservative.

Can sodium metabisulfite be removed from EpiPen?

It can be removed only if the replacement formulation maintains epinephrine potency, impurity control, sterility, container-closure integrity, and device shelf life. Removal alone does not establish pharmaceutical equivalence.

Is a sulfite-free EpiPen automatically safer?

No. A sulfite-free product could reduce sulfite exposure, but it must still control epinephrine oxidation and meet the safety requirements for an injectable emergency product.

Are EpiPen excipients protected by patents?

The basic excipients are generally conventional. Patent value is more likely to arise from specific concentrations, pH ranges, antioxidant combinations, stability profiles, packaging systems, or integration with the auto-injector.

Can a 505(b)(2) applicant develop a new EpiPen formulation?

A 505(b)(2) strategy may be appropriate for a materially changed formulation, device, or presentation that relies partly on existing epinephrine data while requiring new supporting evidence.

References

1. U.S. Food and Drug Administration. (2023). EpiPen and EpiPen Jr epinephrine injection prescribing information.
2. U.S. Food and Drug Administration. (2018). FDA approves first generic versions of EpiPen.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. International Council for Harmonisation. (2003). Q1A(R2): Stability testing of new drug substances and products.
5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary.